Page last updated: 2024-12-10

2-(3-oxo-2,4-dihydroquinoxalin-1-yl)-2-phenyl-N-(4-propan-2-ylphenyl)acetamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

2-(3-oxo-2,4-dihydroquinoxalin-1-yl)-2-phenyl-N-(4-propan-2-ylphenyl)acetamide is a complex organic molecule with a rather lengthy chemical name. It's important to understand what this name tells us about the molecule's structure before discussing its potential research significance.

**Breaking Down the Name**

* **2-(3-oxo-2,4-dihydroquinoxalin-1-yl):** This part describes a substituted quinoxaline ring system.
* **Quinoxaline:** A heterocyclic ring system composed of two fused benzene rings with a nitrogen atom at each junction.
* **3-oxo:** This indicates a carbonyl (C=O) group is attached to the third carbon atom of the quinoxaline ring.
* **2,4-dihydro:** This signifies that the second and fourth positions on the quinoxaline ring are saturated (have two hydrogen atoms attached).
* **1-yl:** This indicates that the quinoxaline ring is attached to the rest of the molecule at the first position.
* **2-phenyl:** This describes a phenyl group (a benzene ring) attached to the second position of the molecule.
* **N-(4-propan-2-ylphenyl):** This refers to an amide group (containing a nitrogen atom) connected to a phenyl group.
* **N-:** This indicates that the amide group is directly attached to the nitrogen atom.
* **4-propan-2-yl:** This indicates an isopropyl group (CH(CH3)2) is attached to the fourth position of the phenyl ring.

**Overall, the molecule can be visualized as:**

* A quinoxaline ring system with a carbonyl group at position 3 and attached to a phenyl group and an amide group.
* The amide group is connected to a phenyl ring that also has an isopropyl group.

**Potential Research Importance**

Due to the complex structure and functional groups present, this molecule could be interesting for research in several areas:

* **Pharmacology:** The presence of the quinoxaline ring and amide group suggests potential for biological activity. Many quinoxaline derivatives have been found to possess antibacterial, antifungal, anti-inflammatory, and anticancer activities. This molecule could be investigated for its potential pharmacological properties.
* **Materials Science:** The presence of both aromatic rings (quinoxaline and phenyl) and a carbonyl group indicates the molecule could exhibit interesting optical or electronic properties. It could be investigated for use in organic electronics, sensors, or other advanced materials.
* **Organic Synthesis:** The complexity of the molecule makes it a potential target for organic synthesis research. Synthesizing this molecule could involve challenging reaction steps and might lead to the development of new synthetic methodologies.

**It's important to note that without specific research context, it's difficult to definitively say why this molecule is important for research. The molecule's actual significance will depend on the specific research questions being investigated.**

Cross-References

ID SourceID
PubMed CID4384031
CHEMBL ID1527084
CHEBI ID114555

Synonyms (16)

Synonym
CHEMDIV3_007555 ,
IDI1_025465
MLS000586757
smr000208687
n-(4-isopropylphenyl)-2-(3-oxo-3,4-dihydroquinoxalin-1(2h)-yl)-2-phenylacetamide
EU-0054660
CHEBI:114555
HMS1494H09
2-(3-oxo-2,4-dihydroquinoxalin-1-yl)-2-phenyl-n-(4-propan-2-ylphenyl)acetamide
n-(4-isopropylphenyl)-2-[3-oxo-3,4-dihydro-1(2h)-quinoxalinyl]-2-phenylacetamide
AKOS001776550
AKOS022028135
CHEMBL1527084
Q27195958
sr-01000548827
SR-01000548827-1
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
amino acid amideAn amide of an amino acid formed formally by conversion of the carboxy group to a carboxamido group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (15)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.22390.003245.467312,589.2998AID2517
LuciferasePhotinus pyralis (common eastern firefly)Potency15.10140.007215.758889.3584AID588342
glp-1 receptor, partialHomo sapiens (human)Potency1.00000.01846.806014.1254AID624417
chaperonin-containing TCP-1 beta subunit homologHomo sapiens (human)Potency11.22023.981127.764939.8107AID504842
ATAD5 protein, partialHomo sapiens (human)Potency14.58100.004110.890331.5287AID504467
USP1 protein, partialHomo sapiens (human)Potency1.25890.031637.5844354.8130AID743255
Smad3Homo sapiens (human)Potency10.00000.00527.809829.0929AID588855
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency31.62280.011212.4002100.0000AID1030
isocitrate dehydrogenase 1, partialHomo sapiens (human)Potency32.46486.309627.099079.4328AID602179; AID624002
serine-protein kinase ATM isoform aHomo sapiens (human)Potency35.48130.707925.111941.2351AID485349
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID540317
mitogen-activated protein kinase 1Homo sapiens (human)Potency10.00000.039816.784239.8107AID1454
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency22.38720.00798.23321,122.0200AID2551
gemininHomo sapiens (human)Potency29.09290.004611.374133.4983AID624296
DNA dC->dU-editing enzyme APOBEC-3F isoform aHomo sapiens (human)Potency17.78280.025911.239831.6228AID602313
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]